SAN LUIS OBISPO, Calif., Oct. 3, 2018 – Oxiplex/IU® is CE marked and available in the European Union. It is an absorbable, synthetic viscoelastic gel that is applied following intrauterine surgery to preserve uterine integrity and improve surgical outcomes by reducing post-surgical adhesions. Learn more at www.fziomed.com, or find us on LinkedIn: www.linkedin.com/company/fziomed-inc.
“We have been a provider of adhesion barriers for gynecological surgery for many years and our customers have requested that the same protection from post-surgical adhesions be made available for use in the uterus,” said John Krelle, President and CEO of FzioMed. “The new delivery system we have developed in conjunction with opinion leaders in the field, enables safe and easy application of gel and preservation of surgical excellence following numerous intrauterine procedures such as; Adhesiolysis, Dilation and Curettage, Myomectomy, Polypectomy, Removal of Retained Products of Conception and Uterine Septum Surgery.”
Several peer reviewed, published journal articles have demonstrated how Oxiplex/IU has enhanced good surgical technique by reducing post-surgical adhesions following intrauterine surgery. These journal articles and other information on Oxiplex/IU are available on our website.
About FzioMed, Inc.
FzioMed, Inc. is a privately held medical device company that develops, manufactures and markets absorbable adhesion barriers based on its patented polymer technology. Our products are sold in more than 70 countries.
FzioMed®, Oxiplex®, Oxiplex/AP®, Interpose®, Oxiplex/IU®, Laresse® and Dynavisc® are registered trademarks of FzioMed, Inc.